1h Free Analyst Time
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide. Speak directly to the analyst to clarify any post sales queries you may have.
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 2, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Respiratory and Gastrointestinal which include indications Binge Eating Disorder, Insomnia, Nicotine Addiction, Obstructive Sleep Apnea, Opium (Opioid) Addiction, Addiction, Alcohol Addiction, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Mild Cognitive Impairment, Narcolepsy, Panic Disorders, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Sleep Disorders and Smoking Cessation.
The latest report Orexin Receptor Type 1 - Drugs In Development, 2021, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
- The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionOrexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview
- Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronos Therapeutics Ltd
- Eisai Co Ltd
- Eolas Therapeutics Inc
- Idorsia Pharmaceutical Ltd
- Indivior Plc
- Inexia Ltd
- Johnson & Johnson
- Merck & Co Inc
- OXonium Therapeutics
- Taisho Pharmaceutical Holdings Co Ltd
- Yangtze River Pharmaceutical Group
- ACT-539313 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CT-010018 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CTDP-002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- daridorexant hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EORA-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- INDV-2000 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- JNJ-3215 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- lemborexant - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- OPN-021 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- suvorexant - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TS-142 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- YZJ-1139 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones
Featured News & Press Releases
- Jun 30, 2021: Eisai launches in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
- Jun 09, 2021: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
- Jun 09, 2021: Eisai to present latest data of Lemborexant at 35th Annual Sleep Meeting
- Mar 10, 2021: FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia
- Mar 03, 2021: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
- Mar 02, 2021: New Drug Approval for in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
- Feb 04, 2021: Health Canada authorizes DAYVIGO (lemborexant)
- Nov 02, 2020: Eisai to present on lemborexant at Digital CTAD 2020
- Oct 28, 2020: Eisai to present on lemborexant at 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference
- Aug 28, 2020: Eisai presents new analyses from phase 3 studies of DAYVIGO (lemborexant) CIV for the treatment of insomnia in adult patients at Virtual SLEEP 2020
- Aug 28, 2020: Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
- Aug 25, 2020: Eisai to present latest data of lemborexant at 34th Annual Sleep Meeting (SLEEP 2020)
- Aug 13, 2020: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
- Aug 06, 2020: Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia - preparation for a local registration program advancing
- Jul 22, 2020: Eisai to present latest data on Lemborexant at the Alzheimer’s Association International Conference (AAIC) 2020
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2021
- Number of Products under Development by Therapy Areas, 2021
- Number of Products under Development by Indication, 2021
- Number of Products under Development by Companies, 2021
- Products under Development by Companies, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Stage and Route of Administration, 2021
- Number of Products by Stage and Molecule Type, 2021
- Pipeline by Chronos Therapeutics Ltd, 2021
- Pipeline by Eisai Co Ltd, 2021
- Pipeline by Eolas Therapeutics Inc, 2021
- Pipeline by Idorsia Pharmaceutical Ltd, 2021
- Pipeline by Indivior Plc, 2021
- Pipeline by Inexia Ltd, 2021
- Pipeline by Johnson & Johnson, 2021
- Pipeline by Merck & Co Inc, 2021
- Pipeline by OXonium Therapeutics, 2021
- Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
- Pipeline by Yangtze River Pharmaceutical Group, 2021
- Dormant Products, 2021
- Discontinued Products, 2021
List of Figures
- Number of Products under Development by Stage of Development, 2021
- Number of Products under Development by Therapy Areas, 2021
- Number of Products under Development by Top 10 Indications, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Molecule Types, 2021
- Number of Products by Stage and Molecule Types, 2021
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Chronos Therapeutics Ltd
- Eisai Co Ltd
- Eolas Therapeutics Inc
- Idorsia Pharmaceutical Ltd
- Indivior Plc
- Inexia Ltd
- Johnson & Johnson
- Merck & Co Inc
- OXonium Therapeutics
- Taisho Pharmaceutical Holdings Co Ltd
- Yangtze River Pharmaceutical Group
